Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Símbolo de cotizaciónTNXP
Nombre de la empresaTonix Pharmaceuticals Holding Corp
Fecha de salida a bolsaMar 29, 2010
Director ejecutivoLederman (Seth)
Número de empleados81
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 29
Dirección26 Main Street, Suite 101
CiudadCHATHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07928
Teléfono12129809155
Sitio Webhttps://www.tonixpharma.com/
Símbolo de cotizaciónTNXP
Fecha de salida a bolsaMar 29, 2010
Director ejecutivoLederman (Seth)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos